Estrasorb-Privacy Statement

Privacy Statement

This Privacy Statement describes how we handle information that you provide to us on this website. Your name, address, and any other personal identifying information you provide may be used by Esprit Pharma, its business partners and consultants to provide you with information about Estrasorb, menopause or other health issues, or to develop services concerning menopause and other health conditions. Esprit Pharma will not sell or rent the personally identifiable medical information collected to any other third party. You can request that your personally identifiable medical information be removed from the database associated with this website at any time. Esprit Pharma uses personally identifiable medical information only with valid permission or other legal authorization. Identified medical information is held and processed under secure conditions with access limited to appropriate Esprit Pharma staff or other authorized agents having a requirement to maintain the confidentiality of the information. In addition to the information you may provide, Esprit Pharma, along with or through its business partners, also collects information from users in two ways:

(a) Web server logs/IP
addresses and (b) cookies. (a) Web Server Logs/IP Addresses: An IP address is a number assigned to your computer whenever you access the Internet. All computer identification on the Internet is conducted with IP addresses, which allows computers and servers to recognize and communicate with each other. Esprit Pharma. collects IP addresses to conduct system administration and report aggregate information to affiliates or business partners to conduct site analysis and website performance review. Esprit Pharma may also use IP addresses to identify users who may threaten sites, users, customers or others.

(b) Cookies
A cookie is a piece of information that the computer that hosts our site gives to your computer (browser) when you access a website. The cookie uniquely identifies your browser to the server so the server can maintain a session. Sessions allow us to store information on the server to help make the Web experience better for you and to conduct site analysis and website performance review. By submitting the information you agree to the above.

Esprit Pharma Privacy Policy Terms of Use Press Releases Legal Statement Contact Us

ESTRASORB is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause. Estrasorb should not be used in women with any of the following conditions: undiagnosed abnormal genital bleeding; known, suspected, or history of cancer of the breast; known or suspected estrogen-dependent neoplasia; active deep-vein thrombosis, pulmonary embolism or history of these conditions; active or recent (eg, within the past year) arterial thromboembolic disease (eg, stroke, myocardial infarction); liver dysfunction or disease. ESTRASORB should not be used in patients with known hypersensitivity to its ingredients; known or suspected pregnancy. There is no indication for ESTRASORB in pregnancy. There appears to be little or no increased risk of birth defects in women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy (see PRECAUTIONS in full Prescribing Information).

Estrogens increase the risk of endometrial cancer. Close clinical surveillance of all women taking estrogen is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is no evidence that the use of "natural" estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogenic doses. (see WARNINGS, Malignant neoplasms, Endometrial cancer).
Cardiovascular and other risks. Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia. (see WARNINGS, Cardiovascular disorders and Dementia).
The Women's Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo (see CLINICAL PHARMACOLOGY, Clinical Studies, Warnings, Cardiovascular disorders and Malignant neoplasms, Breast cancer).
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with oral conjugated estrogens plus medroxyprogesterone acetate relative to placebo.

It is unknown whether or not this finding applies to younger postmenopausal women. (See CLINICAL PHARMACOLOGY, Clinical Studies, Warnings, Dementia and PRECAUTIONS, Geriatric Use). Other doses of conjugated estrogens with medroxyprogesterone acetate, and other combinations of estrogens and progestins were not studied in the WHI and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.